Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:9/24/2008

are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 In today,s increasingly global ... presence to reflect the needs of a global ... meet the needs of key stakeholders while recognizing ... According to recent research by benchmarking firm, ... participating companies averaged more than $100,000 in annual ...
(Date:12/19/2014)... , December 18, 2014 ... application/module that is used to store, manipulate, and ... comprises a patient tracking and scheduling system, result ... of RIS with HIS and other databases improves ... registration and patient scheduling, patient list management, radiology ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... October 21, 2011 At the ... (IDS)   in Barcelona, Spain (20-22 October 2011),   ... long-term, sustained efficacy and safety of   XEOMIN ... with dystonia. Dystonia is a particularly ...
... N.C., Oct. 21, 2011 SPX Corporation (NYSE: ... segment entered into a definitive agreement to acquire ... extraction, evaporation, vacuum and freeze drying technologies to the ... terms of the transaction were not disclosed.  The transaction ...
Cached Medicine Technology:Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4SPX to Acquire e&e, a Global Supplier of Extraction, Evaporation, Vacuum and Freeze Drying Technologies 2SPX to Acquire e&e, a Global Supplier of Extraction, Evaporation, Vacuum and Freeze Drying Technologies 3
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring ... of 1,000 new designs in this collection, and all ... , AngelWeddingDress.com promises to provide the most ... essentials while many fashion trends come and go. If ... team at AngelWeddingDress.com is ready to assist. , ...
(Date:12/21/2014)... Dennis Thompson HealthDay Reporter ... tobacco smokers find e-cigarettes less addictive than traditional cigarettes, new ... often as they did regular cigarettes, thousands of ex-smokers said ... impulsive and irritable over their need to smoke, researchers reported. ... score was significantly less for e-cig use than for tobacco ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... California (PRWEB) December 21, 2014 Serious ... search for Vintage 1967 Jm Morrison and the Doors International ... posters. This would also be the only time that ... concert was on Nov. 25, 1967. According to Hawley, ... D.C. They did play the Alexandria Roller Rink earlier ...
(Date:12/21/2014)... Over the past 39 years, NES ... of emergency departments across the nation, from quality of ... translated into an innovative suite of tools, systems, and ... enhance the patient experience. , NES Health, a ... management services for hospitals, announced the development and launch ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2
... new study shows that Multidetector CT (MDCT) without the use of ... This helps in avoiding the need for surgeons to do ... ,In the past, the best way to find ... contrast media then watch to see if and where the contrast ...
... Previous studies have suggested that drinking a lot of coffee ... result in miscarriage or premature delivery. ,A recent ... of a link between caffeine intake and pregnancy outcome. ... 1,000 women in the initial stages of pregnancy who drank ...
... licenses for inexpensive versions of heart disease and AIDS ... pharmaceutical bigwigs. Health Minister, Mongkol Songkhla, confirmed that the ... ,According to the Health Minister, the drugs are meant ... elaborate on whether the drugs would be generic substitutes ...
... have discovered that learning appears to slow the development of ... The finding suggests that the elderly, by keeping their minds ... The study appears in the Jan. 24 issue of the ... modified mice is the first to show that short but ...
... of the mineral selenium appear to reduce or slow ... selenium have been noted in HIV-positive patients, and evidence ... system function, the researchers report in the Jan. 22 ... ,"Those individuals who were treated with selenium displayed ...
... equally effective alternative therapy for controlling hot flushes and ... derived from progesterone may be as effective as estrogen ... synthetic version of the hormone progesterone, was first made ... available in an oral form – said Dr.Jerilynn Prior, ...
Cached Medicine News:Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2Health News:Selenium Supplements May Slow Progression of HIV: Report 2Health News:Selenium Supplements May Slow Progression of HIV: Report 3
Light weight, clear imaging, attaches easily, perfect size, optional leg, table cart....
... powered torso and leg sections ... Table simultaneously lift body and ... mechanism raises and lowers legs ... positioning. A wide range of ...
... The RX600 is a versatile, fully ... range of built-in traction facilities, a powered ... make it extremely versatile too. ,<br.,In fact ... general surgery as it is for traction ...
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator. , ,Most Appropriate for the Proximal Femur, Metatarsal/Tar...
Medicine Products: